Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing
China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...
NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation
The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...
BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study
BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...
NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs
The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...
Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...
Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...
Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment
The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...
Corestar Biotech Secures Series A Funding for POCT R&D Expansion
Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of...
Great Robotics Raises RMB 100M for Surgical Robot Development
Great Robotics, a Beijing-based medical robotics company, has reportedly raised close to RMB 100 million...
Visum Pharma Series B+ Financing to Advance R&D and GMP Workshop Construction
Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in...
Yunnan Jianzhijia Plans Acquisition of Hebei Tangren Pharmacy in USD 309 Million Deal
China-based Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266) plans to acquire 100% of compatriot firm...
Sun Pharma Loses VBP Bid for Bicalutamide in China Due to Quality Failures
The Shanghai Medical Products Administration (SMPA) has revoked the winning bid of India-based Sun Pharmaceutical...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...
Dakang Medical Secures RMB 400M in Series E Round for Hemodialysis Center Expansion
Dakang Medical (DiaCare Medical), a Beijing-based provider of blood purification chain medical services, has reportedly...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation
Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...
Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization
China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...
NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals
The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...
Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...
Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study
China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...